regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The method is the collection of conditions in which the GC operates for a given analysis. Method development is the process of determining what conditions are adequate and/or ideal for the analysis required. Conditions which can be varied to accommodate a required analysis include inlet temperature, detector temperature, column temperature and temperature program, carrier gas and carrier gas flow rates, the column's stationary phase, diameter and length, inlet type and flow rates, sample size and injection technique. Depending on the detector(s) (see below) installed on the GC, there may be a number of detector conditions that can also be varied. Some GCs also include valves which can change the route of sample and carrier flow. The timing of the opening and closing of these valves can be important to method development.
=== Destruction and preservation === Because of its waterlogged condition the Flag Fen Basin was an area where peat deposits developed around 2000 BC, and they survive there today. The anaerobic conditions generated by silt deposits from the fens protected the wooden posts and rafters of the collapsed structures from rotting away under the influence of air and bacteria. In the 10th century BC the ground level was much lower than today, increasing around 1 mm (0.039 inches) per year as autumnal debris was added to the surface of the fens. By the early Roman period most of the structure was covered and preserved.
PMOS involves both hormonal and metabolic changes. Women with PMOS often have higher levels of androgens, mainly produced by the ovaries, as part of a disrupted hypothalamus–pituitary–ovarian axis. In the brain, the hypothalamus sends out gonadotropin-releasing hormone (GnRH) pulses with higher frequency. This raises luteinising hormone (LH), while follicle-stimulating hormone (FSH) stays the same or is slightly lower. The higher LH stimulates theca cells in the ovary to produce more androgens. The disrupted hormonal environment, including high levels of androgens, suppresses the growth and development of ovarian follicles ("cysts"). This leads to an accumulation of many small follicles, a feature referred to as polycystic ovarian morphology. The lack of ovarian follicle development also leads to a reduction in ovulation. Granulosa cells in these small follicles produce high levels of anti-Müllerian hormone, which reduces the conversion of testosterone to oestradiol (oestrogen). Metabolic changes are common in PMOS. Many women develop insulin resistance, which causes the pancreas to produce extra insulin. High insulin levels reduce liver production of sex hormone-binding globulin (SHBG), increasing free circulating androgens. Low-grade inflammation can worsen insulin resistance, creating a reinforcing loop between metabolic and reproductive disturbances. Insulin resistance is not present only in overweight women with PMOS, but obesity makes it worse. PMOS is associated with cardiovascular and liver dysfunction.
Sources: en.wikipedia.org
=== Stress/ Hypothalamic-pituitary-adrenal (HPA) axis === GHSR1A, Ghrelin's endogenous receptor, is expressed within the hypothalamus including the arcuate nucleus, but not in the paraventricular nucleus (PVN) where ghrelin has been found to indirectly affect HPA axis function via neighboring corticotropin releasing hormone (CRH) neurons. Studies regarding how ghrelin affects cortisol and adrenocorticotropic hormone (ACTH) secretion along with how cortisol and ACTH levels affect ghrelin are inconsistent as different psychological and physical stressors within in-vivo studies have produced a myriad of results as the underlying mechanisms are still not understood well.
== Metabolism and biochemistry == Dietary retinyl acetate is hydrolyzed in the intestinal lumen by pancreatic triglyceride lipase and by brush‑border phospholipase B, releasing free retinol. The retinol is absorbed, re‑esterified mainly with long‑chain fatty acids by lecithin‑retinol acyltransferase (LRAT) inside enterocytes, and secreted in chylomicrons to the liver, where 50–80 % of total‑body vitamin A is stored as retinyl palmitate in hepatic stellate cells. Mobilization of these stores releases retinol bound to retinol‑binding protein 4 (RBP4) for delivery to peripheral tissues.
===== Mass Spectrometry ===== Mass spectrometry methods are unable to determine the folding of nascent polypeptides. No current methods examine the folding states of nascent polypeptides globally in the cell. There are methods for examining the folding state of individual nascent polypeptides. One method uses a nonspecific protease to cleave the nascent peptide at a low temperature. The protease can cleave the unfolded, flexible regions, but cannot cut tightly folded regions. The products of the cleavage can then be separated and studied to determine the folded regions of the nascent peptide.
== Published works == Rowland has published over 270 research articles in international peer-reviewed journals, and over 60 book chapters and conference reports. He co-authored with Thomas Tozer two standard textbooks: Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, now in its 5th edition, and Essentials of Pharmacokinetics and Pharmacodynamics.
Sources: en.wikipedia.org
== X == X-chromosome inactivation A process in female mammals where one of the two X chromosomes is randomly silenced in each cell to balance gene dosage with males. Some neurological disorders, such as Rett syndrome, are influenced by X-inactivation patterns. X-linked adrenoleukodystrophy A genetic disorder affecting the breakdown of very-long-chain fatty acids, leading to their accumulation in the brain and adrenal glands. It causes progressive demyelination and adrenal insufficiency. X-linked intellectual disability A group of inherited cognitive disorders associated with mutations on the X chromosome. Examples include Fragile X syndrome and MECP2 duplication syndrome. Xenon (anesthetic) A noble gas with neuroprotective and anesthetic properties. It has been studied for its NMDA receptor antagonism and minimal side effects on brain function. Xenotransplantation The transplantation of cells or tissues from one species to another for research or therapeutic purposes. In neuroscience, fetal pig or rat neural cells may be studied in primate models to investigate brain repair. Xerostomia A condition of dry mouth that may result from neurological disorders affecting autonomic control of salivary glands, such as Parkinson's disease or side effects of anticholinergic drugs.
=== Mi === August Michaelis (1847–1916), German chemist who discovered the Michaelis–Arbuzov reaction Leonor Michaelis (1875–1949), German biochemist and physical chemist known for fundamental advances in enzyme chemistry Hartmut Michel (born 1948), German biochemist, 1988 Nobel Prize in Chemistry for determination of the first crystal structure of an integral membrane protein Huang Minlon (1889–1979), Chinese chemist, pioneer of modern pharmaceutical industries in China Stanley Miller (1930–2007), American chemist, best known for the Miller–Urey experiment Eugène Millon (1812–1867), French military chemist and physician who discovered the reaction of mercury and nitric acid with egg albumen David P. Mills (PhD 2007), British chemist who investigates lanthanide and actinide f-block elements Luis E. Miramontes (1925–2004), Mexican co-inventor of the combined oral contraceptive pill Peter D. Mitchell (1920–1992), British biochemist known for the theory of chemiosmosis, 1978 Nobel Prize in Chemistry Eilhardt Mitscherlich (1794–1863), German chemist, remembered for the law of isomorphism. Alexander Mitscherlich (1836–1918), German chemist known for discovering crystallographic isomorphism
Raynaud syndrome, also known as Raynaud's phenomenon, is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. Typically the disease affects the fingers, and, less commonly, the toes, though it rarely also affects the nose, ears, nipples, or lips. The episodes classically result in the affected part turning white and then blue. Often, numbness or pain occurs. As blood flow returns, the area turns red and burns. The episodes typically last minutes but can last several hours. The condition is named after the physician Auguste Gabriel Maurice Raynaud, who first described it in his doctoral thesis in 1862. Episodes are typically triggered by cold or emotional stress. Primary Raynaud's is idiopathic (spontaneous and of unknown cause) and not correlated with another disease. Secondary Raynaud's is diagnosed given the presence of an underlying condition and typically is associated with an older age of onset. In comparison to primary Raynaud's, episodes of secondary Raynaud's are more likely to be painful and asymmetric and to progress to digital ulcerations. Secondary Raynaud's can be due to a connective-tissue disorder such as scleroderma or lupus, injuries to the hands, prolonged vibration, smoking, thyroid problems, and certain medications, such as birth control pills and stimulants. Diagnosis is typically based on the symptoms. The primary treatment is avoiding the cold. Other measures include the discontinuation of nicotine or other stimulant use.
In the 1970s, bodybuilding had major publicity thanks to the appearance of Arnold Schwarzenegger, Franco Columbu, Lou Ferrigno, Mike Mentzer and others in the 1977 docudrama Pumping Iron. By this time, the IFBB dominated the competitive bodybuilding landscape and the Amateur Athletic Union (AAU) took a back seat. The National Physique Committee (NPC) was formed in 1981 by Jim Manion, who had just stepped down as chairman of the AAU Physique Committee. The NPC has gone on to become the most successful bodybuilding organization in the United States and is the amateur division of the IFBB. The late 1980s and early 1990s saw the decline of AAU-sponsored bodybuilding contests. In 1999, the AAU voted to discontinue its bodybuilding events.
New Riders of the Purple Sage was an American country rock band. The group emerged from the psychedelic rock scene in San Francisco in 1969 and its original lineup included several members of the Grateful Dead. The band is sometimes referred to as the New Riders or as NRPS.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.